<DOC>
	<DOCNO>NCT00847080</DOCNO>
	<brief_summary>The purpose study determine whether sitagliptin effective treatment reactive hypoglycemia dysinsulinism .</brief_summary>
	<brief_title>Treatment With Sitagliptin Reactive Hypoglycemia Secondary Dysinsulinism</brief_title>
	<detailed_description>Symptomatic reactive hypoglycemia abnormal glucose decrease meal ingestion . Patients abnormality early manifestation glucose intolerance high risk type 2 diabetes . The pathophysiology abnormality appear related delayed first phase insulin release . Improvement first phase insulin secretion delay gastric empty induced sitagliptin phosphate could favorable effect patient delayed insulin secretion associate reactive hypoglycemia .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Clinical biochemical diagnosis prediabetic reactive hypoglycemia Must able swallow tablet Negative pregnancy test ( appropriate ) Renal insufficiency Hepatic insufficiency Diabetes ( type )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Reactive hypoglycemia</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Incretins</keyword>
	<keyword>Prediabetes</keyword>
</DOC>